This article is more than 5 years old. Information may no longer be current.

FDA approves expanded pediatric indication for t:slim pump

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA approved an expanded pediatric indication for the t:slim insulin pump, lowering its indicated age for use in children from those aged at least 12 years to age 6 years, Tandem Diabetes Care announced in a press release.

The t:slim pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the current t:slim pump features, with no changes to the existing user interface.

“The t:slim Pump has the look and feel of a modern consumer device, which we believe makes it especially well-suited for school-aged children who have grown up in a world of smartphones and tablets,” Kim Blickenstaff, president and chief executive officer of Tandem Diabetes Care, said in the release. “This FDA clearance allows us to share this product with a broader group of children with diabetes and their parents, who we think can benefit greatly from our technology.”